Last updated on August 2019

A Study to Assess the Efficacy Safety and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis

Brief description of study

Study of the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of KPL-716 in subjects with prurigo nodularis.

Detailed Study Description

This is a Phase 2a/b randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, PK and immunogenicity of KPL-716 administered subcutaneously (SC) in subjects with prurigo nodularis experiencing pruritus. The Phase 2a portion of the study will enroll up to 100 subjects and will include 2 arms: one active arm and one placebo arm.

Following analysis of the Phase 2a portion of the study (milestone dates above), enrollment into the Phase 2b portion may be initiated.

Clinical Study Identifier: NCT03816891

Find a site near you

Start Over

Site 303

Saint-Jérôme, QC Canada
  Connect »